Navigation Links
Tamoxifen Discontinuation Rates Surprisingly High

A new study, published in the March 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society,// says early termination of this highly effective breast cancer drug may negatively affect treatment efficacy. At 3.5 years, the study also reveals that over one third of women have ceased tamoxifen treatment.

In the clinical practice setting almost a quarter of women treated for breast cancer stop tamoxifen within one year, a rate twice as high as indicated by previous studies. Tamoxifen is a selective estrogen receptor modulator that inhibits the stimulatory effect that estrogen has on the development of specific types of breast cancer. Scientists estimate that over 40,000 recurrences are prevented each year worldwide because of this drug. However, the optimal duration of therapy is five years. Less than five years of continual treatment is associated with higher rates of recurrence and higher mortality rates. The most common reason for discontinuation is adverse effects, including mood swings and hot flashes; these are often successfully treated with a specific antidepressant.

Discontinuation or non-persistence rates estimated by clinical trials range from 16 to 32 percent. Studies of usage outside clinical trials report non-persistence rates of only 17 percent at two years and 31 percent at five years.

However, these rates are compiled from self-reporting data collection methods and target elderly patients – an inherently biased data collection method in a population accustomed to chronic medications. Led by Thomas I. Barron, M.Sc. of the Department of Pharmacology & Therapeutics at Trinity College Dublin & St James's Hospital, Dublin, researchers reviewed pharmaceutical data from a national database of 2816 women aged 35 years and older who started tamoxifen for breast cancer.

The researchers found that at 12 months 22 percent of women had ceased using the drug. At 24 months 28 percent had stopped tam oxifen, and at 3.5 years 35 percent had stopped the treatment without commencing an alternative therapy.

Analysis for risk factors for discontinuing tamoxifen identified age and history of antidepressant use. Women between the ages of 35 and 44 or over 75 as well as women who reportedly used an antidepressant within one year of starting tamoxifen were more likely to stop tamoxifen.

"This study demonstrates that persistence with tamoxifen cannot be assumed and raises concerns about persistence with other oral hormonal therapies for breast cancer and oral anti-neoplastics in general," the authors write. "This is of particular importance," they conclude, "as longer durations of adjuvant therapy may be recommended for breast cancer in the future and as cancer survivorship becomes a priority area in clinical practice and research."



Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Letrozole Beats Tamoxifen in Breast Cancer Therapy
2. Tamoxifen does not adversely affect the brain
3. Tamoxifen reduces breast cancer risk
4. Tamoxifen reduces breast cancer risk
5. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
6. Tamoxifen Ineffective In Presence Of Genetic Variation in Breast Cancer
7. New Drug More Effective than Tamoxifen in Preventing Breast Cancer Relapse
8. Raloxifene Better Than Tamoxifen For Breast Cancer
9. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
10. Study Identifies Mechanism Which May Help Tamoxifen Work Better
11. Tamoxifen Yields Long-term Reduction in Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... ... May 04, 2016 , ... International ... scheduled on July 25-27, 2016 at Las Vegas. It aims to bring together ... educational institutes and research organizations across the globe; making the conference a perfect ...
(Date:5/4/2016)... ... May 04, 2016 , ... Netc , a leading provider of barcode ... Style Printing, Inc. The Dataware acquisition enables Netc to continue to grow its label business, ... Label Stock provides customers with the ability to print and label tape media on site ...
(Date:5/3/2016)... ... May 04, 2016 , ... ... That message is reaching the global health community through expanding activities that embrace ... of cancer in the resource-limited countries. , In support of this ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ProIntro Glitch is ... Pro X. Pixel Film Studios’ titles allow users to add a terrifying opener to ... such as boxes, lines and accents. To add greater contrast, all the user has ...
(Date:5/3/2016)... ... May 03, 2016 , ... In April, Amerec launched ... latest technologies to help find the best steam and sauna solutions. , First, the ... responsive design. This improvement brings all of the site’s features, especially the Steam ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... , May 2, 2016 Leading Economies with Fastest ... 10.2 Côte d,Ivoire 8.6 Uzbekistan 8 Ireland 7.8 India 7.3, , ... BRICS nations , which comprises of Brazil , ... and South Africa , registered the fastest GDP growth ... in China , recession in Brazil ...
(Date:5/2/2016)... N.J. , May 2, 2016  Celsion ... development company, today announced data from the first ... escalating clinical trial (the OVATION Study) combining GEN-1, ... care for the treatment of newly-diagnosed patients with ... followed by interval debulking surgery.  In the first ...
(Date:4/29/2016)... PUNE, India , April 29, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" market research report ... pipeline, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ...
Breaking Medicine Technology: